Ipsen's ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases.
Ipsen Pty Ltd has been in operation since 2001. It is the Australian affiliate of a global specialty driven company with total sales exceeding €1.225 billion in 2014.
Its development strategy is supported by franchises: neurology / Dysport®, oncology-endocrinology / Somatuline®, uro-oncology / Diphereline®.
The website was built under a strict adherence to brand outlines as governed by the parent company in France.
Pharmaceutical companies are closely regulated by Australian legislation. The laws provide a framework that ensures companies operate to the highest ethical standards and practices. In addition, the research-based pharmaceutical industry established its own Code of Conduct setting standards for ethical marketing and promotion of prescription medicines in Australia. This is known as the Medicines Australia Code of Conduct. The code complements the many legislative regulations for the pharmaceutical industry that are set by our government. Abiding by the Code is compulsory for members of Medicines Australia, but it is voluntary for all other medicines companies.
Easily accessible Consumer Medicine Information (CMI) and Product Information (PI) leaflets are located on the website as are details of clinical trials and a list of any organinsations that receive financial contributions.